ABL Bio’s Stomach Cancer Drug Shows Promise in Once 'Untreatable' Patients
South Korean platform biotech company ABL Bio announced that development remains firmly on track despite investor concerns over Sanofi’s recent...
Search results for "Lee Sang-hoon"
AI Cancer Gene Analysis and 810 Billion-Won Tech Export Lead South Korea's Top 30 Health Care R&D Achievements
The Ministry of Health and Welfare and the Korea Health Industry Development Institute announced on the 8th that they have selected the "2026 Health...
Osteoporosis Treatment: The Era of Relying Solely on Bone Mineral Density Is Over
The central focus of osteoporosis care is undergoing a significant shift. No longer does a diagnosis begin and end with...
ABL Bio to Present Two Bispecific Antibody ADC Posters at AACR
ABL Bio announced on the 19th that it will participate in this year’s American Association for Cancer Research Annual...
Hanmi Pharmaceutical, CEO Park Jae-hyun Steps Down: Hwang Sang-yeon Appointed as New CEO Candidate
Hanmi Science is replacing CEO Park Jae-hyun of its subsidiary Hanmi Pharmaceutical and forming a new board of...
FDA Approves Clinical Trial for Abl Bio’s Dual-Antibody ADC Candidate
Abl Bio announced on March 3rd that the U.S. Food and Drug Administration has approved the Investigational New Drug...
ABL Bio Publishes Review Paper on Dual Antibodies in International Journal
ABL Bio announced on the 11th that it published a review paper on the next-generation immune-oncology dual antibody...
Abl Bio Confirms Positive Effects of Cancer Drug 'ABL111' in Phase 1b Clinical Trial
Abl Bio announced on the 7th that it has confirmed positive anti-cancer efficacy in the dose expansion cohort of the...
1